BioMaxima (BMX.WA) Stock Price

BioMaxima Price

GPW·CLOSED
10.06
​
Market closed

Over the last 16 years BioMaxima grew revenue by 14.8% annually, reaching 60.90 M PLN. Earnings per share have declined at 10.4% per year over the last 16 years. For BioMaxima, the net margin of 0.2% is down versus 13.0% a few years ago. At today's price the dividend yield works out to roughly 4.97%. The payout ratio is around 358% of earnings. The dividend has grown at 22.3% per year over the past 8 years. The consensus 12-month price target for BioMaxima is 26.93 PLN, about 167.7% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.

BioMaxima stock price

Access this data via the Eulerpool API

BioMaxima business model & stock analysis

Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

Frequently asked questions about BioMaxima

Analysts currently set an average price target of 26.93 PLN for the BioMaxima stock (median: 26.93 PLN), implying +167.7 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the BioMaxima stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioMaxima to generate revenue of 76.80 M PLN and earnings per share of 1.90 PLN.

Converted at the current exchange rate, the BioMaxima share trades at 2.29 EUR (10.06 PLN).

The BioMaxima share (BMX.WA) is listed on 3 stock exchanges, including: Frankfurt (944.F).

The expected revenue of BioMaxima is 76.80 M PLN. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BioMaxima is 7.96 M PLN. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BioMaxima is currently 5.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioMaxima stock.

The price-to-sales ratio (P/S) of BioMaxima is currently 0.55. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioMaxima stock.

The Eulerpool Quality Score for BioMaxima is 3/10.

The ISIN of BioMaxima is PLBIOMX00015. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BioMaxima is A1C5AE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BioMaxima is BMX.WA. The ticker symbol is used to trade BioMaxima shares on the stock exchange.

Fair ValueTerminal
9.46 PLN
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Poland
Currency
PLN
Initial public offering
Jun 8, 2010
ISIN
PLBIOMX00015
Cusip
X0725P102
Market capitalization
42.15 M PLNMicro Cap
52-Week Range
PEG
39.06
P/E ratio
P/Ee 2026
5.29
P/Ee 2027
3.59
P/Ee 2028
3.35
P/Ee 2029
3.35
P/Ee 2030
3.25
P/S
P/Se
0.55
EV/EBIT
—
P/B Ratio
0.88
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.17 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
5.96 %
Payout Ratio
163.31 %
Dividend growth Ø5Y
20.11 %
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
19.00 %
Last updated Oct 13, 2026, 7:40 PM

BioMaxima Peer Group

BioMaxima Ticker

FRANKFURT · 944.FWARSAW · BMX.WAWSE · BMX.WA

BioMaxima FIGI

BMX:PW · BBG000BBN6S3BMXPLN:XS · BBG00PQ2WHN3BMXPLN:XH · BBG00PQ2WHR9BMXPLN:XF · BBG00PQ2WHT7BMXPLN:XD · BBG00PQ2WHV4BMXPLN:XE · BBG00PQ2WHW3BMXPLN:XJ · BBG00PQ2WHX2BMXPLN:XL · BBG00PQ2WHY1BMXPLN:XG · BBG00PQ2WHZ0BMXPLN:XO · BBG00PQ2WJ04BMXPLN:XN · BBG00PQ2WJ13BMXPLN:XA · BBG00PQ2WJ40

All fundamentals and in-depth analysis of BioMaxima

Our stock analysis for BioMaxima stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioMaxima. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.